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Abstract
Colorectal cancer (CRC) remains one of the major causes of death worldwide, despite steady improvement in early detection
and overall survival over the past decade. Current treatment paradigms, with chemotherapy and biologics, appear to have
reached their maximum benefit. Immunotherapy, especially with checkpoint inhibitors, has shown considerable clinical
benefit in various cancers, including mismatch-repair-deficient CRC. This has led to the planning and initiation of several
clinical trials evaluating novel immunotherapy agents—as single agents, combinations and in conjunction with chemotherapy—in patients with CRC. This article reviews biological and preclinical data for checkpoint inhibitors and discusses various immunotherapy trials in CRC, as well as current efforts in CRC immunotherapy.
Key words: immunotherapy; colorectal cancer; checkpoint inhibition/blockade; programmed death 1 (PD-1); cytotoxic Tlymphocyte-associated antigen 4 (CTLA-4); vaccine; pembrolizumab

Introduction
Colorectal cancer (CRC) is the third most common cancer in
males and the second most common in females [1]. At the time
of diagnosis, more than 20% of patients have metastatic disease
and the survival rate of CRC patients with distant metastasis is
estimated to be 12% [2–4]. Although, due to significant strides in
surgical management, chemotherapy and biological therapy,
average survival for advanced disease now approaches 30
months, metastatic CRC still remains the fourth most common
cause of death from cancer.
The significance of the immune system in the biology of CRC
is emphasized by retrospective assessments of immune infiltrates in resected CRC tumors. The presence of tumor infiltrating lymphocytes—especially CD8 þ lymphocytes—in the tumor
microenvironment, as well as regional lymph nodes, has been

linked to better prognosis [5]. Also, increased infiltration of specific regions of the CRC tumors by cytotoxic memory T lymphocytes (CD8 þ CD45RO þ T-cells) is highly correlated with reduced
risk of recurrence of CRC and better survival [6, 7]. It is also
known that the presence of these effector memory T-cells is
more important than naı̈ve T-cells in reducing the risk of relapse and improving survival. The prognostic significance of Tcells—unlike other inflammatory cells—argues that cancer
immunotherapies modulating T-cell responses could lead to
improved survival.
Recent developments in immune-biotechnology and the discovery of immunotherapy agents—specifically checkpoint inhibitors—have been promising for treatment of melanoma [8, 9]
and non–small cell lung cancer [10], leading to regulatory approval of these novel drugs. The significant activity of these
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agents in various epithelial tumors raises the prospect that the
immune system may represent a favorable avenue for advancing the management of patients with CRC. This review focuses
on current utilization of checkpoint blockade, as well as other
immunotherapy agents, and their potential integration into existing therapeutic regimens for advanced colorectal cancers.

Immune checkpoints: biology and
preclinical studies

Cytotoxic T-lymphocyte-associated antigen 4
There are several membrane protein ligands on antigen presenting cells (APC), which interact with specific receptors on Tcells to produce a co-stimulatory signal or a co-inhibitory signal
to enhance or decrease the T-cell immune response. B7 protein
found on activated APC can pair with CD28 on T-cells, leading
to amplification of TCR signaling, or cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4) (CD152) surface protein on a
T-cell inhibiting T-cell activation and cytokine production with
induction of a state of anergy and proliferative arrest [11].

Figure 1. Checkpoint blockade in tumor immunotherapy. T-cells initiate the immune response though recognition of antigenic peptides presented by the MHC on the
surface of antigen-presenting cells and cancer cells through their TCR. TCR engagement alone is insufficient to turn on a T-cell response, and additional co-stimulatory
signal via B7 are required for cytokine production, targeT-cell lysis and effector cell responses. B7 protein can pair with CD28 on T-cells, leading to amplification of TCR
signaling, or CTLA-4 on a T-cell inhibiting T-cell activation. PD-1 primarily inhibits effector T-cell activity in the effector phase within tissue and tumors—unlike CTLA4, which mainly modulates early steps in T-cell activation. PD-1 inhibitory receptor is expressed by T-cells during long-term antigen exposure and results in inhibition
of T-cells on interaction with PD-L1, which is expressed in the tumor microenvironment. Immune checkpoint blockade via monoclonal antibodies leads to preferential
activation of cancer-specific T-cells and revival of tumor immunity (MHC: major histocompatibility complex; TCR: T-cell receptor; CTLA-4: cytotoxic T-lymphocyteassociated antigen 4; PD-1: programmed death 1; PD-L1: programmed death-ligand 1).
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T-lymphocytes act as the chief effector cells in the immune response against tumor cells by recognizing and mounting a cytotoxic response against antigenic molecules arising out of the
genetic and epigenetic alterations that mark malignant transformation. The immune response is initiated by the recognition
of antigenic peptides presented by the major histocompatibility
complex (MHC) on the surface of antigen-presenting cells by the
T-cell receptor (TCR). TCR engagement alone is insufficient to
lead to the clonal expansion and differentiation required for an
effective and lasting immune response against the offending
antigen. Additional co-stimulatory signals are required for cytokine production, targeT-cell lysis and effector cell responses
(Figure 1). There also exists an intricate system of inhibitory signals (immune checkpoints), which is crucial in the maintenance

of peripheral immune-tolerance and preventing autoimmunity. The amplitude and duration of the T-cell response
depends on the balance between co-stimulatory and inhibitory
signals. T-cell responses may be amplified by agonists of costimulatory receptors or antagonists of inhibitory signals. As
the immune checkpoints are often co-opted by tumors to escape immune surveillance, inhibitors of immune checkpoints
lead to revival of tumor immunity. The two checkpoint targets
that have been studied more extensively in cancer are the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed death 1 (PD-1) receptor (Figure 1). Other targets, like
lymphocyte activation gene 3 (LAG-3), are also being studied
and early phase clinical trials are under way.

Immune checkpoints and immunotherapy for colorectal cancer

Programmed death 1
Programmed death 1 (PD-1) primarily inhibits effector T-cell activity in the effector phase within tissue and tumors—unlike
CTLA-4, which mainly modulates early steps in T-cell activation
[19]. PD-1 binds to two distinct members of the B7 family: programmed-death ligands 1 and 2 (PD-L1 and PD-L2). PD-L1 has a
very broad expression range, which includes hematopoietic
cells such as dendritic cells (DC), macrophages, T-cells and B
cells, as well as non-hematopoietic cells such as epithelial and
endothelial cells [20, 21]. PD-L2 has a more restricted expression
profile limited to macrophages, DC and masT-cells. PD-1deficient mice develop a delayed-onset, organ-specific autoimmunity, which is in contrast with the rapid-onset systemic
autoimmunity that characterizes CTLA-4-deficient mice [22].
When BALB/c mice bearing CT-26 colon tumors were treated
with anti-PD-1 antibodies as single-agents, there was growth retardation but no eradication of tumors, which notably could be
accomplished with dual blockade of PD-1 and CTLA-4 [23]. Iwai
et al. intravenously injected PD-1 knockout mice (PD-1-/-) and
wild-type (WT) mice with CT26 colon cancer cells to mimic metastatic spread, and found that tumor formation in the lungs
was significantly reduced in the PD-1-/- mice. Treatment with
anti-PD-1 antibodies also had the same effect [24]. The addition
of anti-PD-L1 antibodies was reported to potentiate the survival
benefit imparted by IL-15 in a metastatic colorectal cancer murine model. The greatest survival benefit in this study was
observed when IL-15 was combined with anti-PD-L1 and antiCTLA-4 treatment [25]; in a syngeneic murine colon cancer
model, anti-PD-L1, when combined with ionizing radiation, effectively controlled tumor growth, which could not be achieved
with either treatment alone, indicating synergy or an abscopal
effect with radiation therapy [26].
While single or dual checkpoint blockade causes significant
improvements in anti-tumor immune response, there is potential to further boost this response with additional immunesensitizing strategies. In one study, treatment with anti-PD-1 or
anti-PD-L1 or anti-CTLA4 alone caused CT-26 colon tumors to
be rejected in 25%, 33%, and 50% of the mice injected, respectively, which increased to 75% with dual blockade. Remarkably,
a complete (100%) tumor rejection was observed when dual
blockade was combined with a cancer vaccine, GVAX [27].

Lymphocyte activation gene 3
Lymphocyte activation gene 3 (LAG-3) is another molecule expressed on activated T-cells, with diverse biological effects on
T-cell function. Its main ligand is MHC class II, and LAG-3/MHC
class II interaction down-regulates antigen-dependent stimulation of CD4þ T lymphocytes [28]. The protein negatively regulates the cellular proliferation, activation, and homeostasis of
T-cells in a similar fashion to CTLA-4 and PD-1, and has been reported to play a role in the Treg suppressive function [29–31].
LAG-3 also helps to maintain CD8þ T-cells in a tolerogenic state
[32] and, working with PD-1, helps to maintain CD8 exhaustion
during chronic viral infection [33].

Immunotherapy for colorectal cancer
Non-specific immunotherapy and immunomodulatory
effects of chemotherapy
Cytokines such as interferon (IFN), interleukins and granulocyte
macrophage colony-stimulating factor (GM-CSF) constitute
non-specific immunotherapy, which augments host immunity
against tumor antigens. Conventional chemotherapies also
may have some effect through the immune system. Oxaliplatin
triggers a form of cell death that is thought to be immunogenic,
whereas the chemical analogue cisplatin does not trigger the
same form of immunogenic cell death. In preclinical models, injection with oxaliplatin-killed CRC cells enhances the survival
of mice that are subsequently challenged with live CRC cells
and this protection requires an intact immune system [34]; thus
the anti-tumor activity of oxaliplatin may also be related to its
efficacy as an immune-modulatory agent and not solely as a cytotoxic drug.
A Phase II trial of gemcitabine, oxaliplatin and 5-fluorouracil
(GOLF), combined with IL-2 and GM-CSF immune-adjuvant regimen (GOLFIG) in patients with CRC showed an overall response
rate (ORR) of 56.5% and mean overall survival (OS) of nearly 19
months. Autoimmunity and substantial increase in lymphocyte
count were found to be predictors for OS [35]. The GOLFIG-2
chemo-immunotherapy trial was a Phase II I multicenter
study comparing GOLFIG with 5-fluorouracil/leucovorin plus
oxaliplatin (FOLFOX) in chemotherapy-naı̈ve, metastatic CRC
patients. The study suffered early termination because of poor
recruitment in the control arm, but GOLFIG showed superiority
over FOLFOX in terms of progression free survival (PFS) and
ORR, with a trend towards improvement of OS [36]. These findings provide proof-of-principle that chemo-immunotherapy
may represent a novel option for first-line treatment of metastatic CRC.

Immune checkpoint inhibitors
The development of checkpoint inhibitors is largely responsible
for the recent excitement about immunotherapy. These agents
are blocking antibodies to inhibitory cell-surface molecules,
such as CTLA4 and PD-1/PD-L1, which restrain the priming and
effector phases, respectively, of the adaptive T-cell immune response. The PD-1 pathway is a negative feedback system that
represses Th1 cytotoxic immune responses. It is up-regulated in
many tumors and, in their surrounding microenvironment and
its blockade with antibodies to PD-1 or its ligands, has led to remarkable clinical responses in patients with various types of
cancer [10, 37–39]. The expression of PD-1 ligands (PD-L1 or PDL2) on the surface of tumor cells or immune cells is an
important—but not a definitive—predictive biomarker of
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The crucial role of CTLA4-B7 interaction in immune homeostasis is demonstrated by the fact that CTLA-4 knockout mice
develop lethal lymphoproloferative disorders [12]. Regulatory Tlymphocytes (Treg) exhibit the constitutive expression of CTLA-4
and their suppressive function in vivo can be suppressed by
blocking CTLA-4 [13, 14]. Allison et al. reported in 1996 that
blocking CTLA-4 function could not only enhance rejection of
transplanted colon carcinoma in mice, but also delay the
growth of established tumors [15]. In a CT-26 colon carcinoma
model, a combination of an anti-CTLA-4 monoclonal antibody
with ixabepilone or paclitaxel resulted in a 50–70% tumor rejection rate [16]. An enhanced anti-tumor response at the primary
site—as well as an abscopal effect—was observed when fractionated radiotherapy was combined with an anti-CTLA-4
monoclonal antibody in a murine colon cancer model MCA38
[17]. In another study that utilized the same model, a combination of anti-CTLA-4 and anti-4-1BB-enhanced CD8 T-cell mediated anti-tumor response and significantly reduced liver
metastasis when compared with treatment utilizing either antibody alone [18].
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response to PD-1 blockade [38–41]. The clinical activity of checkpoint inhibitors in CRC needs to be evaluated in larger numbers
of patients, in trials that examine predictive biomarkers, as well
as combine these agents with conventional therapies. Table 1
summarizes the results of checkpoint inhibitor clinical trials in
patients with CRC.

Anti-PD-1/PD-L1

Mismatch repair deficiency and checkpoint inhibition
A dMMR system is present in 10–20% of patients with sporadic
CRC and is associated with a favorable prognosis in early-stage
disease. In contrast, dMMR occurs in only 3–6% of patients with
advanced CRC [47, 48]. As the immune system can recognize somatic mutations found in tumors [49]—and as colorectal tumors
with dMMR have several times as many somatic mutations as
proficient MMR tumors [50, 51]—it has been hypothesized that
the immune system may play a role in dMMR tumors possessing a reduced metastatic potential. Additionally, dMMR cancers
have prominent lymphocyte infiltrates [52, 53], which supports
the above hypothesis. Furthermore, recent findings have suggested that the infiltrate in dMMR CRC is more likely to express
PD-L1, which may predict response to PD-1 blockade [54]. Thus
checkpoint inhibitors may have increased activity in dMMR

CTLA-4
Tremelimumab is a fully human IgG2 monoclonal antibody that
blocks the inhibitory action of CTLA-4, and was tested as a
monotherapy in a single-arm, Phase II trial in 47 patients with
refractory metastatic CRC [55]. All the patients were heavily pretreated and most had also received cetuximab. Tremelimumab
did not show significant single-agent activity in this study,
which could be due to delayed immune responses in the setting
of advanced CRC, since 43 of 45 patients experienced disease
progression with a median duration on study of only 2.3
months. The first FDA-approved CTLA-4 monoclonal antibody,
ipilimumab, is currently being evaluated in combination with
nivolumab (anti-PD-1 antibody) in clinical trials for metastatic
CRC patients with dMMR tumors (NCT02060188).

Other immune checkpoint inhibitors
Tumors with mismatch repair deficiency also have a high
expression of immune checkpoint ligands such as PD-L1, PD-1,
CTLA-4, and LAG-3, which effectively counterbalance the active
Th1 response and prevent tumor elimination. These immune
checkpoints function as possible targets for inhibition during
cancer immunotherapy [56]. Anti-LAG-3 monoclonal antibodies
(BMS-986016), alone and in combination with nivolumab, are
already undergoing evaluation in clinical trials (NCT01968109).
These are promising future targets for immune checkpoint
inhibition.

Vaccine-based immunotherapy
Whole-tumor-cell vaccines
The earliest attempts to generate anti-CRC immune responses
were in the form of whole-tumor-cell vaccines. Most studies
have used autologous CRC tumor cells in combination with
Bacillus Calmette-Guérin (BCG). The Eastern Cooperative
Oncology Group (ECOG) E5283 was a randomized, Phase II I trial
that randomly assigned 412 patients with resected stage II and
III colon cancer to an observation arm or a treatment arm with
autologous tumor-cell-BCG vaccine. After a median follow-up of
7.6 years, no statistically significant differences were seen in
terms of clinical outcomes but effective immune responses—
observed as delayed cutaneous hypersensitivity (measured as
skin induration)—correlated positively with disease-free survival (DFS) and OS [57]. Another trial assessed the efficacy of
three post-operative vaccinations, followed by a booster dose 6
months later, in 254 resected stage II and III CRC patients. The
study showed a 44% reduction in risk of recurrence in the vaccine group [58]. This study showed the importance of vaccine
quality control for proper immunogenicity, as 12% of vaccines
in the ECOG trial failed to meet quality control specifications.
Delayed cutaneous hypersensitivity was also shown to be an effective surrogate endpoint in monitoring the long-term efficacy
of tumor cell vaccines [59]. A meta-analysis of all trials evaluating this strategy in resected stage II and stage III CRC reported a
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The anti–PD-1 antibody nivolumab did not demonstrate clinically significant activity in a Phase I study of multiple tumor
types, which included 17 patients with heavily pre-treated, metastatic CRC. However, six of the seven tumors found in this cohort, which were tested for PD-L1 expression, were negative,
potentially explaining the observed lack of response [37].
Notably, one patient from this metastatic-CRC cohort, who had
a PD-L1 positive tumor and was treated with 5 doses of nivolumab, showed complete response after 6 months and no signs of
disease after 3 years. This patient’s tumor was also mismatchrepair-deficient [42].
Pembrolizumab is a humanized IgG4 monoclonal antibody
that blocks the interaction of PD-1 with its ligands PD-L1 and
PD-L2. A Phase II trial of pembrolizumab evaluated 32 patients
with advanced CRC [11 with deficient mismatch repair (dMMR)
and 21 with proficient mismatch repair (pMMR)] [43]. All patients enrolled in the study had received two or more (median
of four) previous chemotherapy regimens, except one patient
who had received one chemotherapy regimen and one non-PD1 based immunotherapy before. The immune-related objective
response rate and patients with stable disease were significantly higher in the dMMR CRC patients (40% and 78%, respectively) than in the pMMR CRC patients (0% and 11%,
respectively). Similar findings were observed in the cohort with
dMMR cancers other than CRC. Based on this a larger, Phase II
study (Keynote-164) is currently enrolling patients to assess the
benefit of pembrolizumab for unresectable or metastatic dMMR
CRC refractory to two or more previous lines of therapy
(NCT02460198).
The anti–PD-L1 antibody BMS936559 showed no activity in a
Phase I trial that included 18 patients with CRC [44]. However,
preliminary data with another anti–PD-L1 antibody MPDL3280A
showed activity in CRC with one of four patients achieving a durable partial response [45]. Another Phase Ib trial, assessing
MPDL3280A in combination with bevacizumab in refractory CRC
patients and in combination with FOLFOX plus bevacizumab in
first-line CRC, showed good tolerability and clinical activity
[unconfirmed ORR 8% (1/13) and 44% (8/18), respectively] [46].

tumors, a hypothesis which was tested in a Phase II trial. This
study showed that MMR status may be a predictive biomarker
for clinical benefit from checkpoint inhibition [43]. Although immunotherapy in dMMR tumors holds great promise, the complete absence of response in patients with pMMR CRC—who
represent the vast majority—highlights the ongoing need to understand why patients with conventional CRC lack robust responses to immunotherapy.

Phase II non-randomized, 3
centers

Phase I

Phase I

Phase I

Phase Ib

Phase 2, singlearm,
multicenter

Le et al. [43]

Topalian et al. [37]

Brahmer et al. [44]

Herbst et al. [40, 45]

Bendell et al. [46]

Chung et al. [55]

The only responding patient had deficient
MMR and PD-L1 positive tumor
-

Patient post-treatment
after 48 weeks

Combinations well tolerated. No worsening
of bevacizumab or
chemotherapy-associated adverse events.

No clinically meaningful
single-agent activity

-

Ongoing response at 60
weeks

For responders, PFS
range 10–61 weeks

PFS : 2.3 months (95% CI,
2.1–2.6 months)

Arm A: 8% (1/13)
PR: 1 patient SD: 9 patients PD: 3 patients
Arm B: 40% (12/30)
PR: 12 patients SD: 14
patients PD: 4 patients

PR : 1 patient
PD: 43 patients

Metastatic CRC, pretreated with any or
combination of 5-FU,
oxaliplatin, irinotecan
and cetuximab (n ¼ 47
patients)

PR: 1 patient

Pretreated CRC (n ¼ 4
patients)

Arm A: Pretreated, metastatic CRC (3 prior
regimens) (n ¼ 14
patients)
Arm B: Oxaliplatin naı̈ve
metastatic CRC (n ¼ 30
patients; 23/30 as first
line therapy)

No objective responses

Pre-treated, metastatic
CRC (n ¼ 18 patients)

4.8 months (95% CI, 4.1
to 7.7 months)

-

-

-

-

-

CR: 1 patient

High somatic mutation
load associated with
prolonged PFS
(P ¼ 0.02).

Cohort A: Median PFS
not reached
Cohort B: Median PFS –
2.2 months

Cohort A: Median OS not
reached
Cohort B: Median OS - 5
months

Cohort A: 40% (4/10
patients)
Cohort B: 0% (0/18
patients)

Metastatic CRC, pretreated with 2
regimens
Cohort A : MMR deficient CRC (11 patients)
Cohort B : MMR proficient CRC (21 patients)
Heavily pre-treated,
metastatic CRC (n ¼ 17
patients)

Pembrolizumab (anti
PD-1) 10 mg/kg IV every 14 days

Nivolumab (anti PD-1) at
doses of 1, 3, or 10 mg/
kg every 2 weeks (in
dose escalation
phase)
BMS-936559 (anti PD-L1)
at doses of 0.3, 1, 3,
and 10 mg/kg on days
1, 15, and 29 of 6week cycle
MPDL3280A (anti-PD-L1)
at doses of1, 3, 10, 15
and 20 mg/kg IV every
3 weeks
MPDL3280A (anti-PD-L1)
Arm A: MPDL3280A
20 mg/
kg þ bevacizumab
15 mg/kg every 3
weeks
Arm B: MPDL3280A
14 mg/
kg þ mFOLFOX6 þ bevacizumab 10 mg/kg every 2 weeks
Tremelimumab (antiCTLA-4) 15 mg/kg IV
on day 1 of every 90day cycle.

Other findings

Progression-free
survival

Overall survival

Objective response rate

Patient population

Therapy
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PD-MMR ¼ mismatch repair; PFS ¼ progression-free survival; PR ¼ partial response; RR ¼ response rate; SD ¼ stable disease

CR ¼ complete response; CRC ¼ colorectal cancer; CTLA-4 ¼ cytotoxic T-lymphocyte-associated protein 4; IV ¼ intravenous; L1 ¼ programmed death ligand 1; OS ¼ overall survival; PD ¼ progressive disease; PD-1 ¼ programmed death 1;

Trial phase

Author

Table 1. Checkpoint inhibition in colorectal cancer: clinical trials
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Peptide vaccines
Peptide vaccines incorporate one or more short or long amino
acid sequences as tumor antigens, combined with a vaccine adjuvant. Several TAAs expressed by colorectal cancer cells—such
as carcino-embryonic antigen (CEA), MUC-1, survivin, beta-human chorionic gonadotropin (hCG) and ring finger protein 43
(RNF43)—have been targeted via peptide vaccines. Results have
been modest, with only a few patients showing clinical response, despite demonstration of antigen-specific T-cell responses following vaccination.
A Phase I safety study, using plasmid DNA vaccine-encoding
CEA (CEA66 DNA) alongside GM-CSF in CRC patients, showed
good tolerability with no signs of autoimmunity [64]. In another
Phase I trial, HLA-A24-specific survivin-2B vaccine was administered to 15 patients with advanced or recurrent CRC expressing
survivin, with one patient showing an increase in survivin-specific CTLs and six showing decreased CEA levels [65]. A cohort of
21 CRC patients, treated with a peptide-cocktail vaccine derived
from RNF43 and translocase of the outer mitochondrial membrane 34 (TOMM34), showed antigen-specific CTL responses to
both RNF43 and TOMM34 in 8/21 and CTL response to only one
of the peptides in 12 out of 21 patients. Interestingly, survival
rates were lowest in the patients who showed no CTL responses
[66]. Another TAA of interest is hCG, which is not produced by
normal colorectal epithelial and mucosal cells or benign lesions.
Moulton et al. studied the effect of hCG peptide vaccination in
77 patients with stage IV CRC, most of whom had a history of
chemotherapy with one or more agents; anti-hCG antibodies
were observed in 56 out of 77 patients and a longer survival was
seen in patients with higher-than-median levels of antibody
[67].

Viral vector vaccines
The immunogenicity of peptide vaccines is low, and could be
amplified by packaging the peptide in a viral or bacterial vector.
Several groups have attempted to use immunogenic viral vectors expressing CRC TAAs to stimulate anti-CRC immune responses. A Phase I study with ALVAC-CEA, a canary pox virus
expressing CEA and B7.1 co-stimulation, exhibited an acceptable safety profile in 118 patients. Objective responses were

seen in 42 (40%) patients, whereas another 42 (40%) had stable
disease, with several patients demonstrating CEA-specific T-cell
responses [68]. Similar results were seen with a recombinant
fowl pox virus expressing multiple co-stimulatory molecules
(B7.1, LFA-3, ICAM-1) and the CEA antigen—administered alone
or in sequence with a recombinant vaccinia virus expressing
the same molecules—to patients with a variety of CEAexpressing tumors, including 35 patients with CRC. Most patients showed an increase in CEA-specific T-cells, and durable
disease stability of at least 4 months was observed in 40% of patients (23 out of 58).

Dendritic cell vaccines
Dendritic cells (DCs) are crucial for cell surface presentation of
endogenous and exogenous immunogenic peptides and activation of T-cells. Various strategies for delivering TAAs to DCs
through synthetic peptides [69], tumor RNA [70], and tumor cell
lysates [71] have been developed to stimulate an adequate CTL
response. Phase I clinical studies using autologous human DCs,
pulsed with CEA peptide, in CEA-expressing metastatic CRC patients showed the vaccine to be safe and well tolerated,
although only a modest clinical improvement was observed
[72]. Another Phase I study used CEA-derived peptide loaded
onto DCs, plus a vaccine adjuvant (Flt3-ligand). After vaccination, 2 of 12 patients experienced dramatic tumor regression,
one patient had a mixed response, and two exhibited stable disease [73]. Antigen selection remains a key issue with these dendritic cell–based vaccination approaches, and overall success
rates have been modest.

Adoptive cell transfer therapy
Adoptive cell transfer therapy (ACT) is a technique in which autologous T-cells are extracted from patients, activated, expanded in vitro and re-injected into patients. Adoptive cell
therapies have shown some activity in CRC, using autologous Tcells genetically engineered to express high-affinity receptors
for CRC TAAs. ACT enables the selection and activation of
highly reactive T-cells, with clinical responses observed even in
advanced CRC [74]. In a Phase I study, autologous T-cells, genetically engineered to express a high-affinity murine T-cell receptor against human CEA, were administered to three patients
with refractory CRC. Serum CEA levels decreased significantly
(74–99% reduction) in all patients and one patient exhibited an
objective decrease in tumor size. But further enrollment of
patients was halted because all three patients developed autoimmune colitis (two patients with grade 3) [75]. This was the
first study in which an objective regression was noted in metastatic colorectal cancer through ACT. Morgan et al. used HER2specific chimeric antigen receptor (CAR) T-cells for patients
with metastatic CRC, but failed to demonstrate its safety and efficacy due to severe side-effects [76]. Further studies on this
front could possibly lead to safe and efficacious ACT therapy for
CRC. Various trials are in progress in this field of investigation,
including a Phase I dose escalation of infusion of CTLs specific
for TAAs NY-ESO-1, MA-GEA4, PRAME, Survivin, and SSX in relapsed or refractory solid tumors (NCT02239861), and a Phase I/
II study of the safety and efficacy of infusion of peripheral blood
lymphocytes transduced with a CAR that is specific for VEGF-2
in metastatic CRC following a lympho-depleting conditioning
regimen
with
cyclophosphamide
and
fludarabine
(NCT01218867).
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significant improvement in OS (HR ¼ 0.76; P ¼ 0.007) and DFS
(HR ¼ 0.76; P ¼ 0.03) [59].
As observed in early trials, autologous whole-tumor-cell vaccines were poorly immunogenic, which was probably due to
paucity of tumor-associated antigens (TAAs) in whole-cell vaccines and the large proportion of antigens shared with normal
cells [60]. Another tumor-cell vaccine approach, utilizing
Newcastle disease virus-infected, irradiated, autologous tumor
cells (ATV-NDV) was tested in a Phase II trial. Of patients treated
with ATV-NDV, 61% developed tumor recurrence, compared
with 87% treated with surgery alone [61]; however, in terms of
overall survival, a Phase II I trial with 50 patients failed to show
significant improvement for ATV-NDV-treated patients, although a sub-group analysis showed benefit for colon—but not
rectal—cancer patients [62].
GVAX, a GM-CSF gene-transfected tumor-cell vaccine, has
shown immune-stimulatory action in several cancers [63].
There is a current pilot study using GVAX in irradiated autologous CRC cells in patients with stage IV CRC, which examines
safety as a primary endpoint, as well as progression-free survival (PFS) and OS (NCT01952730).

Immune checkpoints and immunotherapy for colorectal cancer

Special considerations with immunotherapy

Future directions
The approval of more drugs in this novel class of immune
checkpoint inhibitors—as well as development of several newer
immunotherapies that are undergoing testing in clinical trials—
would continue to provide innovative insights relevant to future
investigations of CRC immunotherapy. Although PD-L1 expression and dMMR tumors are currently showing promise as predictive biomarkers for response to checkpoint inhibitors, it is
necessary to identify specific patient sub-groups, in the appropriate clinical setting, that would benefit most from
immunotherapy.
It is also imperative to study rational combinations involving
immunotherapy drugs. Given the evidence for immunogenic
cell death triggered by oxaliplatin, the combination of first-line
FOLFOX chemotherapy and checkpoint inhibition holds significant promise. As checkpoint inhibitors are thought to enhance
pre-existing immune response to tumor antigens by releasing
tumor-induced inhibition of the immune response, combinations of antigen-directed therapies (e.g. vaccines), sequentially
followed by checkpoint inhibition, may also be a rational approach in CRC.
Another novel strategy being currently evaluated involves
stimulation of anti-tumor immune response using urelumab
that activates co-stimulatory CD137 receptor. Combining this
approach with checkpoint inhibition (activate co-stimulatory
receptors and inhibit co-inhibitory receptors) appears promising
and a Phase I trial of urelumab in combination with nivolumab
is currently enrolling subjects (NCT02534506). Another clinical

trial of urelumab in combination with cetuximab is also underway in metastatic CRC patients (NCT02110082).

Conclusion
Current clinical trials of immunotherapy in CRC—specifically
checkpoint inhibitors—are already suggesting its efficacy in
carefully selected subsets of patients with CRC. Developing reliable, predictive biomarkers and understanding the mechanisms
that underlie lack of response or resistance to these agents remains a challenge. Based on their demonstrated effectiveness
in a broad range of solid malignancies, immunotherapies hold
great promise in CRC.
Conflict of interest statement: none declared.
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